A detailed history of China Universal Asset Management Co., Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 10,490 shares of SUPN stock, worth $272,844. This represents 0.05% of its overall portfolio holdings.

Number of Shares
10,490
Previous 10,490 -0.0%
Holding current value
$272,844
Previous $358,000 0.28%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$27.11 - $35.17 $113,211 - $146,869
4,176 Added 66.14%
10,490 $358,000
Q4 2023

May 21, 2024

SELL
$22.72 - $29.68 $94,878 - $123,943
-4,176 Reduced 39.81%
6,314 $182,000
Q4 2023

Jan 23, 2024

BUY
$22.72 - $29.68 $111,623 - $145,817
4,913 Added 350.68%
6,314 $183,000
Q3 2023

May 21, 2024

BUY
$27.57 - $32.91 $18,940 - $22,609
687 Added 96.22%
1,401 $38,000
Q3 2023

Oct 30, 2023

BUY
$27.57 - $32.91 $18,940 - $22,609
687 Added 96.22%
1,401 $39,000
Q2 2023

May 21, 2024

SELL
$29.91 - $38.73 $568 - $735
-19 Reduced 2.59%
714 $21,000
Q2 2023

Jul 27, 2023

SELL
$29.91 - $38.73 $568 - $735
-19 Reduced 2.59%
714 $21,000
Q1 2023

May 21, 2024

BUY
$34.93 - $42.03 $6,427 - $7,733
184 Added 33.52%
733 $26,000
Q1 2023

Apr 27, 2023

BUY
$34.93 - $42.03 $6,427 - $7,733
184 Added 33.52%
733 $27,000
Q4 2022

May 21, 2024

SELL
$31.09 - $37.88 $309,065 - $376,565
-9,941 Reduced 94.77%
549 $19,000
Q4 2022

Jan 31, 2023

BUY
$31.09 - $37.88 $1,492 - $1,818
48 Added 9.58%
549 $20,000
Q3 2022

Oct 21, 2022

BUY
$28.79 - $35.41 $14,423 - $17,740
501 New
501 $17,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.39B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.